The obesity pharmacology landscape is dominated by GLP-1 receptor agonists and other agents with significant tolerability concerns. The possibility that a compound already widely used in agriculture — with an established safety profile in that context — could meaningfully address metabolic dysfunction opens a genuinely intriguing line of inquiry, even if the evidence remains firmly preclinical.
The compound under investigation, 6-benzylaminopurine (BAP), is a synthetic cytokinin routinely applied to crops to regulate plant cell division and fruit development. When administered orally to diet-induced obese CD-1 mice of both sexes, BAP produced significant body weight reduction through sex-divergent mechanisms encompassing appetite suppression, white adipose tissue browning, and enhanced lipid oxidation. On the metabolic side, treated animals showed improvements in glucose tolerance, fasting blood glucose, leptin levels, insulin sensitivity, and markers of liver health. Mechanistically, RNA-sequencing identified suppression of EGFR/ErbB2 and MEK/ERK/EGR1 signaling cascades as central to BAP's action. In both murine and human hypothalamic neuronal models, BAP downregulated the orexigenic neuropeptide Y (NPY) while upregulating the appetite-suppressing peptide POMC — effects partially attributable to MEK/ERK inhibition. The same pathway also appeared to drive upregulation of uncoupling protein 1 (UCP1) in adipocytes, suggesting a shared molecular mechanism across metabolically relevant tissue types.
Contextually, MEK/ERK signaling has been explored as a metabolic target before, but leveraging a phytohormone to modulate it is a novel angle. The findings are preliminary in meaningful ways: all in vivo work is in mice, and the CD-1 outbred strain, while metabolically responsive, is not a gold-standard obesity model. Sex-specific mechanisms were noted but not fully characterized. Translation to humans involves unknown hurdles around pharmacokinetics, dosing, and long-term safety at therapeutic concentrations. That said, the dual action on central appetite regulation and peripheral adipose thermogenesis — via a single orally bioavailable compound — is an architecturally attractive profile. This is incremental-to-promising early-stage research that warrants follow-up in more rigorous rodent models and, eventually, primate safety studies before any human relevance can be claimed.